News

FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
Fierce Biotech3d
FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...
US FDA pauses Gilead trials testing experimental HIV pill combination
The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...
STAT2d
Gilead pauses trials of HIV combination therapy
RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb , licensed an experimental drug and diagnostic agent for ...
BioSpace3d
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
FDA placed clinical hold on Gilead HIV treatment trials of GS-1720
The Food and Drug Administration has placed a clinical hold on Gilead’s (GILD) HIV treatment trials of GS-1720 and/or GS-4182 ...
US FDA places clinical hold on Gilead trials testing HIV pill combination
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
MPR2d
FDA Puts Clinical Hold on Gilead’s Trials for Two HIV Drug Candidates
Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...
Why Gilead Scinces Stock Tumbled on Tuesday
On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...
A New Shot Prevents HIV—and Breathes New Life Into a Stagnant Biotech
After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.
STAT2d
Pharmalittle: We’re reading about Trump and drug prices, Gilead trial delays, and more
Trump administration officials are expected to release more details on their plan to lower prescription drug prices in the ...